Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Cainan Foltz

Gastroenterology San Diego, CA Medical Doctor

NPI 1033434071 CMS profile 1451

8008 Frost St Ste 200, San Diego, CA 92123

Open in the dashboard

General payments

$6,863

323 records reported · program years 2019–2025

Research payments

$1,849

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$252,899 paid to institutions, not to them · program years 2021–2025

Through program year 2025, Cainan Foltz of San Diego, CA is reported in the CMS Open Payments database as having received $6,863 across 323 general payments and $1,849 in research payments paid to them. Separately, studies naming them as principal investigator received $252,899 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 78th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,172 54
2025 Research $1,849 2
2024 General $1,542 64
2023 General $1,237 52
2022 General $1,186 60
2021 General $447 23
2020 General $334 17
2019 General $945 53

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cainan Foltz
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Cainan Foltz were reported at $1,172. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Cainan Foltz Gastroenterology median Middle half National median
2019 $945 $417 $126–$1,100 $163
2020 $334 $224 $74–$624 $114
2021 $447 $352 $106–$1,054 $132
2022 $1,186 $448 $129–$1,270 $149
2023 $1,237 $533 $150–$1,390 $160
2024 $1,542 $605 $160–$1,606 $164
2025 $1,172 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,128 106 payments
  2. Janssen Biotech, Inc. $916 41 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $643 26 payments
  4. Pfizer Inc. $497 22 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $389 19 payments
  6. Intercept Pharmaceuticals, Inc. $319 15 payments
  7. Regeneron Healthcare Solutions, Inc. $268 9 payments
  8. Gilead Sciences, Inc. $250 16 payments
  9. Genzyme Corporation $175 5 payments
  10. Ferring Pharmaceuticals Inc. $133 8 payments
  11. Other $1,147 56 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,764 322 payments
  2. Education $99 1 payment
Products named General payments · program years 2019–2025
  1. RINVOQ $979 49 payments
  2. STELARA $842 37 payments
  3. SKYRIZI $525 23 payments
  4. SIMPONI ARIA $393 21 payments
  5. SIMPONI $393 21 payments
  6. ENTYVIO $387 14 payments
  7. HUMIRA $350 20 payments
  8. LINZESS $337 21 payments
  9. TREMFYA $317 14 payments
  10. XIFAXAN $305 14 payments
  11. Other $3,907 192 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $1,849 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

589

Median for Gastroenterology: 569

Drug cost

$249,258

Median for Gastroenterology: $104,976

Branded share of claims

39.7%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 33 $119,156
Humira(Cf) Pen Adalimumab Brand 12 $81,738
Linzess Linaclotide Brand 20 $9,994
Budesonide Ec Budesonide Brand 15 $9,507
Mesalamine Generic 31 $8,881
Movantik Naloxegol Oxalate Brand 19 $7,726
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 123 $6,942
Pantoprazole Sodium Generic 175 $1,886
Dexlansoprazole Dr Dexlansoprazole Brand 12 $1,170
Omeprazole Generic 98 $984

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$86,605

Medicare's payments for the services billed

Medicare patients

333

Average age 74

Services billed

880

168 women, 165 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 47%
Diabetes 34%
Ischemic heart disease 25%
Depression 24%
Chronic kidney disease 22%
Atrial fibrillation 21%
Cancer 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $273
$273 — —
STELARA
  • Janssen Biotech, Inc. $167
$167 — —
VELSIPITY
  • PFIZER INC. $149
$149 — —
DUPIXENT
  • GENZYME CORPORATION $81
  • Regeneron Healthcare Solutions, Inc. $28
$109 — —
SKYRIZI
  • AbbVie, Inc. $96
$96 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

325 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record